Navigation Links
IntegenX Awarded DTRA Contract to Develop Pathogen Detection and Identification Platform
Date:10/8/2010

PLEASANTON, Calif., Oct. 8 /PRNewswire/ -- IntegenX, Inc. (IXI) today announced that it has been awarded a new contract by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to develop an Integrated Sample-to-Sequence (ISS) system for rapid detection and identification of genetically engineered bacteria and viruses, medically relevant bacteria and viruses, and emerging pathogens. IntegenX will use its Universal Sample Preparation Module (USPM), created under a previous Department of Defense contract, to purify DNA from pathogen targets contained in complex matrices and present the purified material to an IntegenX library construction module, followed by an amplification module and a next-generation sequencing (NGS) module.

IntegenX will be the prime contractor for a first phase of $2.8 million and a possible 22-month, $14.8 million contract. The company will apply its patented MOVe™ technology to integrate the complete workflow of the ISS system, which will have a small footprint of less than 3 cubic feet and will be operated with minimal user interaction by a non-specialist.

"The ISS System will provide DoD and the country with a much-needed system to detect genetically engineered and emerging pathogens. This will help protect our country, and others, against genetically engineered bioagents. There is no system to detect such threats today," said Dr. Stevan Jovanovich, CEO and President of IntegenX.

"Our experience in next-generation sequencing library preparation and making a sample-to-answer system for forensic human identity testing has uniquely positioned IntegenX to accomplish the requirements that DTRA has requested," added Ezra van Gelder, Executive Vice President of Research and Development. "IntegenX technology integrates the processes to incorporate the complex steps into a complete and straightforward sample-to-sequence workflow."

About IntegenXIntegenX, Inc., headquartered in Pleasanton, CA, is a privately held company that designs, manufactures and markets automated DNA- and RNA-based sample preparation systems for life sciences, applied sciences, and diagnostics markets. IntegenX products eliminate the most acute pain points affecting widely adopted laboratory workflows. The company's expertise and intellectual property is based on its patented MOVe™ valve technology. The microfluidics technology platform integrates advanced fluidics and analytical robotic capabilities to produce sample-to-answer performance for DNA and RNA sequencing, DNA-based forensics and human identity (HID) testing, biodefense, as well as molecular diagnostics applications. The company's first commercial platform, the Apollo 100(TM) System, is used to optimally prepare DNA for sequencing. IntegenX will soon release the Apollo 324 system to resolve the fragmented workflows in next-generation sequencing library preparation. IntegenX has successfully tested a sample-to-answer platform for human DNA identification, slated for commercialization in 2011. For more information, please visit http://www.integenx.com.Contact:Howard D. GoldsteinIntegenX, Inc.5720 Stoneridge Drive, Suite 300Pleasanton, CA 94568925.701.3481howardg@integenX.com This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>

SOURCE IntegenX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nanoimprint lithography NSF grant awarded to micro device lab at Stevens
2. BioNanomatrix Founder and CSO Dr. Han Cao Awarded Chinese Rising Star Entrepreneur Award
3. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
4. YM BioSciences licensee Pulmokine awarded NIH funding to develop small molecule drugs for pulmonary hypertension
5. PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
6. Genomas Awarded US Patent for its PhyzioGenomics Platform Technology to Predict Treatment Responses
7. Elusys Awarded Additional $40.6 Million Under Existing U.S. Government Contract to Fund Advanced Development of Anthim, a New Treatment for Anthrax
8. Isolux Corsan Awarded a Contract for the Construction of an Ethanol Plant in Colombia
9. Laser pioneer Federico Capasso awarded Berthold Leibinger Zukunftspreis
10. San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry
11. Flad Architects Awarded Livermore Valley Open Campus Master Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
Breaking Biology News(10 mins):